MOVICOL® has compelling clinical evidence in support of its indicated use. Below are some of the commonly referred to clinical papers:
MOVICOL has Level 1, Grade A clinical evidence for efficacy and safety in the treatment of Constipation – Ramkumar & Rao
MOVICOL is more effective compared to Lactulose – Lee-Robichaud H et al. The Cochrane Library 2010, Issue 7.
MOVICOL is more effective and equally well tolerated compared to fibre (ispaghula husk)
– Wang H-J et al
MOVICOL acts faster to relieve constipation post-op than Coloxyl and Senna - Madsen L et al
MOVICOL recommended as first line laxative for Opioid induced constipation - Wirz S & Klaschik E
MOVICOL-Half in Children demonstrated to be effective and well tolerated in the treatment of constipation – Hardikar W, Cranswick N & Heine RG.
MOVICOL is effective and well tolerated in Parkinsons Disease associated constipation
– Gruss H-J & Ulm G
MOVICOL is effective and well tolerated in constipation due to spinal cord injury or disease
– Kalke YB et al
MOVICOL is effective and well tolerated in the management of constipation in a disabled population - Migeon-Duballet I et al
For a full reference list click here.
For more information and to obtain copies of these and other peer reviewed clinical studies examining the use of MOVICOL, please contact us.